Boston Scientific Corp. (BSX) Scheduled to Post Earnings on Thursday
Boston Scientific Corp. (NYSE:BSX) is scheduled to release its Q313 earnings data on Thursday, October 24th. Analysts expect Boston Scientific Corp. to post earnings of $0.09 per share and revenue of $1.73 billion for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.08. The company had revenue of $1.81 billion for the quarter, compared to the consensus estimate of $1.78 billion. During the same quarter in the previous year, the company posted $0.17 earnings per share. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. On average, analysts expect Boston Scientific Corp. to post $0.44 EPS for the current fiscal year and $0.51 EPS for the next fiscal year.
Shares of Boston Scientific Corp. (NYSE:BSX) opened at 12.29 on Wednesday. Boston Scientific Corp. has a 1-year low of $5.04 and a 1-year high of $12.16. The stock’s 50-day moving average is $11. and its 200-day moving average is $9.12. The company’s market cap is $16.504 billion.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific Corp. in a research note to investors on Wednesday, October 9th. They now have a $12.00 price target on the stock. On the ratings front, analysts at CL King downgraded shares of Boston Scientific Corp. from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday, September 10th. Finally, analysts at Barclays reiterated a “buy” rating on shares of Boston Scientific Corp. in a research note to investors on Wednesday, September 4th. They now have a $12.00 price target on the stock. Fourteen research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $9.69.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.